HCW Biologics (HCWB) to Release Quarterly Earnings on Wednesday

HCW Biologics (NASDAQ:HCWB) will likely be releasing its results before the market opens on Wednesday, April 1st. Analysts expect HCW Biologics to post earnings of ($0.84) per share and revenue of $7.0120 million for the quarter.

HCW Biologics Trading Down 17.9%

HCWB stock opened at $0.43 on Wednesday. The firm has a 50 day moving average of $0.86 and a 200-day moving average of $2.17. The company has a market cap of $1.50 million, a price-to-earnings ratio of -0.04 and a beta of 0.79. HCW Biologics has a 12-month low of $0.39 and a 12-month high of $17.80.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in HCW Biologics stock. Armistice Capital LLC bought a new stake in shares of HCW Biologics Inc. (NASDAQ:HCWB) during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 300,180 shares of the company’s stock, valued at approximately $291,000. Armistice Capital LLC owned about 9.15% of HCW Biologics as of its most recent filing with the SEC. 2.96% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of HCW Biologics in a research note on Thursday, January 22nd. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $35.00.

HCW Biologics Company Profile

HCW Biologics Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases.